Prevalence of HIV Infection among U.S. Hodgkin Lymphoma Cases

Shiels, Meredith S.; Koritzinsky, Erik H.; Clarke, Christina A.; Suneja, Gita; Morton, Lindsay M.; Engels, Eric A.

doi:10.1158/1055-9965.epi-13-0865

Cited by 64 publications

(57 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Excisional biopsy revealed recurrent EBV-positive (EBV 1 ) cHL lymphoma, MC subtype. CD4 1 count was 145 cells per mm 3 and HIV viral load remained undetectable. 18 FDG-PET revealed no extranodal disease ( Figure 2D).…”

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 92%

“…After 2 cycles, CT showed no disease, and he proceeded to autologous stem cell transplant (auto-SCT) following carmustine, etoposide, cytarabine, and melphalan conditioning. CD4 1 count 3 months posttransplant was 186 cells per mm 3 . The patient has been followed on cART for 7 years with no relapse, undetectable HIV with CD4…”

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 96%

“…Disclosures The authors, Associate Editor Jacob M. Rowe, and CME questions author Laurie Barclay, freelance writer and reviewer, Medscape, LLC, declare no competing financial interests. was 140 cells per mm 3 . He commenced tenofovir, lamivudine, and ritonavir-boosted atazanavir for HIV, as well as trimethoprim/ sulfamethoxazole for Pneumocystis pneumonia prophylaxis.…”

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 99%

“…1 count was 173 cells per mm 3 . Twelve months after completing chemotherapy, a new axillary lymph node was palpated.…”

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 99%

“…3 Unlike HIVassociated NHL (HIV-NHL), in which incidence decreased by 50% after introduction of cART (mainly owing to decreases in immunoblastic histologic types), 5,6 HIV-cHL risk has remained stable and burden of disease has increased. 2,6,7 In the United States, cHL follows NHL, Kaposi sarcoma, lung cancer, and anal cancer as the fifth commonest tumor in the setting of HIV.…”

Section: Epidemiology Chl In Patients With Hivmentioning

confidence: 99%

See 4 more Smart Citations

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus

Uldrick

Little

2015

Blood

View full text Add to dashboard Cite

HIV-associated classical Hodgkin lymphoma (HIV-cHL) is an important complication of HIV disease in the era of effective combination antiretroviral therapy (cART). Generally, newly diagnosed HIV-cHL should be managed with curative intent. With modern HIV therapeutics, HIV-cHL treatment outcomes are largely comparable to those of the background population with cHL (non–HIV-cHL). To achieve these outcomes, particular attention must be given to managing HIV. This management includes understanding HIV as a comorbid condition with a spectrum of impact that is unique to each patient. Meticulous attention to drug-drug interactions is required to avoid toxicity and pharmacokinetic effects that can undermine cure. Relapsed and refractory HIV-cHL poses additional therapeutic challenges. The standard management in this setting should also be based on that for non–HIV-cHL, and includes the use of salvage chemotherapy followed by autologous stem cell transplant in chemosensitive disease. The role of allogeneic hematopoietic stem cell transplant is less clear but may be useful in select cases. Newer agents with activity in cHL are being tested as part of primary and salvage therapy and are also highly relevant for HIV-cHL.

show abstract

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 92%

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 96%

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 99%

“…1 count was 173 cells per mm 3 . Twelve months after completing chemotherapy, a new axillary lymph node was palpated.…”

Section: Medscape Continuing Medical Education Onlinementioning

confidence: 99%

Section: Epidemiology Chl In Patients With Hivmentioning

confidence: 99%

See 3 more Smart Citations

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus

Uldrick

Little

2015

Blood

View full text Add to dashboard Cite

show abstract

Cancers Attributable to Infections in the US in 2017

Volesky-Avellaneda,

Morais,

Walter

et al. 2023

JAMA Oncol

Self Cite

View full text Add to dashboard Cite

ImportanceInfections are largely modifiable causes of cancer. However, there remains untapped potential for preventing and treating carcinogenic infections in the US.ObjectiveTo estimate the percentage and number of incident cancers attributable to infections in the US among adults and children for the most recent year cancer incidence data were available (2017).Data SourcesA literature search from 1946 onward was performed in MEDLINE on January 6, 2023, to obtain the data required to calculate population attributable fractions for 31 infection-cancer pairs. National Health and Nutrition Examination Survey data were used to estimate the population prevalence of hepatitis B and C viruses and Helicobacter pylori.Study SelectionStudies conducted in the US or other Western countries were selected according to specific infection-cancer criteria.Data Extraction and SynthesisData from 128 studies were meta-analyzed to obtain the magnitude of an infection-cancer association or prevalence of the infection within cancer cells.Main Outcomes and MeasuresThe proportion of cancer incidence attributable to 8 infections.ResultsOf the 1 666 102 cancers diagnosed in 2017 among individuals aged 20 years or older in the US, 71 485 (4.3%; 95% CI, 3.1%-5.3%) were attributable to infections. Human papillomavirus (n = 38 230) was responsible for the most cancers, followed by H pylori (n = 10 624), hepatitis C virus (n = 9006), Epstein-Barr virus (n = 7581), hepatitis B virus (n = 2310), Merkel cell polyomavirus (n = 2000), Kaposi sarcoma–associated herpesvirus (n = 1075), and human T-cell lymphotropic virus type 1 (n = 659). Cancers with the most infection-attributable cases were cervical (human papillomavirus; n = 12 829), gastric (H pylori and Epstein-Barr virus; n = 12 565), oropharynx (human papillomavirus; n = 12 430), and hepatocellular carcinoma (hepatitis B and C viruses; n = 10 017). The burden of infection-attributable cancers as a proportion of total cancer incidence ranged from 9.6% (95% CI, 9.2%-10.0%) for women aged 20 to 34 years to 3.2% (95% CI, 2.4%-3.8%) for women aged 65 years or older and from 6.1% (95% CI, 5.2%-7.0%) for men aged 20 to 34 years to 3.3% (95% CI, 1.9%-4.4%) for men aged 65 years or older. Among those aged 19 years or younger, 2.2% (95% CI, 1.3%-3.0%) of cancers diagnosed in 2017 were attributable to Epstein-Barr virus.Conclusions and RelevanceInfections were estimated to be responsible for 4.3% of cancers diagnosed among adults in the US in 2017 and, therefore, represent an important target for cancer prevention efforts.

show abstract

Neoplasms in People Living with Human Immunodeficiency Virus

Wang¹,

Chiao²

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

People living with human immunodeficiency viruses (PLWH) are at increased risk for developing malignancies, particularly virally mediated cancers such as Kaposi sarcoma (KS), some types of lymphoma, and HPV‐related cancers, such as cervical cancer and anal cancer. PLWH also have higher rates of alcohol and tobacco use, which increases their risk of non‐virally mediated cancers, such as lung cancer and both oropharyngeal and non‐oropharyngeal head and neck cancers. KS and lymphomas tend to occur at lower CD4 counts, and the incidences of these cancers have decreased since the advent of effective combination antiretroviral therapy (ART). However, the incidence for virally mediated cancers (such as anal cancer) other non‐virally‐mediated non‐acquired immunodeficiency syndrome‐defining cancers (such as lung cancer) have risen in the past decade in part because PLWH are living longer with wide‐spread access to ART. In the past, PLWH with cancers often had lower survival and poorer outcomes due to severe immunodeficiency and poor performance status. In the modern ART era, survival and outcomes for individuals with human immunodeficiency virus (HIV)‐associated lymphomas are generally similar to the HIV‐negative population using standard rituximab‐based multi‐agent chemotherapy. For PLWH with other solid tumors, standard of care treatment is also currently recommended. Active areas of research for cancers in PLWH includes cancer prevention, immunotherapy, and continued development of new therapeutics to improve outcomes.

show abstract

Prevalence of HIV Infection among U.S. Hodgkin Lymphoma Cases

Cited by 64 publications

References 23 publications

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus

How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus

Cancers Attributable to Infections in the US in 2017

Neoplasms in People Living with Human Immunodeficiency Virus

Contact Info

Product

Resources

About